Laboratorio Reig Jofre S.A (RJF) - Net Assets
Based on the latest financial reports, Laboratorio Reig Jofre S.A (RJF) has net assets worth €216.97 Million EUR (≈ $253.66 Million USD) as of September 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€355.15 Million ≈ $415.21 Million USD) and total liabilities (€138.18 Million ≈ $161.54 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check RJF asset liquidity ratio to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €216.97 Million |
| % of Total Assets | 61.09% |
| Annual Growth Rate | 9.15% |
| 5-Year Change | 15.98% |
| 10-Year Change | 69.57% |
| Growth Volatility | 46.95 |
Laboratorio Reig Jofre S.A - Net Assets Trend (2004–2024)
This chart illustrates how Laboratorio Reig Jofre S.A's net assets have evolved over time, based on quarterly financial data. Also explore RJF asset base for the complete picture of this company's asset base.
Annual Net Assets for Laboratorio Reig Jofre S.A (2004–2024)
The table below shows the annual net assets of Laboratorio Reig Jofre S.A from 2004 to 2024. For live valuation and market cap data, see RJF company net worth.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | €213.95 Million ≈ $250.13 Million |
+4.75% |
| 2023-12-31 | €204.25 Million ≈ $238.79 Million |
+4.99% |
| 2022-12-31 | €194.55 Million ≈ $227.45 Million |
+3.20% |
| 2021-12-31 | €188.51 Million ≈ $220.39 Million |
+2.19% |
| 2020-12-31 | €184.48 Million ≈ $215.67 Million |
+3.56% |
| 2019-12-31 | €178.14 Million ≈ $208.26 Million |
+18.97% |
| 2018-12-31 | €149.74 Million ≈ $175.06 Million |
+5.78% |
| 2017-12-31 | €141.56 Million ≈ $165.50 Million |
+6.20% |
| 2016-12-31 | €133.29 Million ≈ $155.83 Million |
+5.64% |
| 2015-12-31 | €126.17 Million ≈ $147.51 Million |
+6.77% |
| 2014-12-31 | €118.17 Million ≈ $138.16 Million |
+164.35% |
| 2014-09-30 | €44.70 Million ≈ $52.26 Million |
-40.88% |
| 2013-12-31 | €75.62 Million ≈ $88.40 Million |
-12.84% |
| 2012-12-31 | €86.75 Million ≈ $101.42 Million |
+0.19% |
| 2011-12-31 | €86.59 Million ≈ $101.23 Million |
+18.04% |
| 2010-12-31 | €73.35 Million ≈ $85.76 Million |
-21.62% |
| 2009-12-31 | €93.59 Million ≈ $109.41 Million |
-29.07% |
| 2008-12-31 | €131.95 Million ≈ $154.26 Million |
-6.36% |
| 2007-12-31 | €140.91 Million ≈ $164.74 Million |
-4.62% |
| 2006-12-31 | €147.74 Million ≈ $172.72 Million |
+86.43% |
| 2005-12-31 | €79.25 Million ≈ $92.65 Million |
+113.37% |
| 2004-12-31 | €37.14 Million ≈ $43.42 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Laboratorio Reig Jofre S.A's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 239.6% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | €10.38 Million | 4.85% |
| Common Stock | €40.45 Million | 18.90% |
| Other Components | €163.14 Million | 76.24% |
| Total Equity | €213.97 Million | 100.00% |
Laboratorio Reig Jofre S.A Competitors by Market Cap
The table below lists competitors of Laboratorio Reig Jofre S.A ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Bonny Worldwide Ltd
TW:8467
|
$221.39 Million |
|
Context Therapeutics Inc
NASDAQ:CNTX
|
$221.43 Million |
|
Perdana Karya Perkasa Tbk
JK:PKPK
|
$221.49 Million |
|
Hexindo Adiperkasa Tbk
JK:HEXA
|
$221.49 Million |
|
SmartRent Inc
NYSE:SMRT
|
$221.36 Million |
|
Neon Equity AG
XETRA:D77
|
$221.13 Million |
|
Hanyang Digitech Co. Ltd
KQ:078350
|
$220.89 Million |
|
Ziprecruiter Inc
NYSE:ZIP
|
$220.83 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Laboratorio Reig Jofre S.A's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 204,351,000 to 213,968,000, a change of 9,617,000 (4.7%).
- Net income of 10,382,000 contributed positively to equity growth.
- Dividend payments of 25,000 reduced retained earnings.
- Share repurchases of 3,000 reduced equity.
- Other comprehensive income decreased equity by 105,858,000.
- Other factors increased equity by 105,121,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | €10.38 Million | +4.85% |
| Dividends Paid | €25.00K | -0.01% |
| Share Repurchases | €3.00K | -0.0% |
| Other Comprehensive Income | €-105.86 Million | -49.47% |
| Other Changes | €105.12 Million | +49.13% |
| Total Change | €- | 4.71% |
Book Value vs Market Value Analysis
This analysis compares Laboratorio Reig Jofre S.A's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 1.05x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has increased from 0.70x to 1.05x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2004-12-31 | €4.02 | €2.80 | x |
| 2005-12-31 | €7.37 | €2.80 | x |
| 2006-12-31 | €8.99 | €2.80 | x |
| 2007-12-31 | €8.57 | €2.80 | x |
| 2008-12-31 | €8.22 | €2.80 | x |
| 2009-12-31 | €5.79 | €2.80 | x |
| 2010-12-31 | €4.52 | €2.80 | x |
| 2011-12-31 | €5.34 | €2.80 | x |
| 2012-12-31 | €5.35 | €2.80 | x |
| 2013-12-31 | €4.66 | €2.80 | x |
| 2014-12-31 | €1.88 | €2.80 | x |
| 2015-12-31 | €2.00 | €2.80 | x |
| 2016-12-31 | €2.12 | €2.80 | x |
| 2017-12-31 | €2.17 | €2.80 | x |
| 2018-12-31 | €2.28 | €2.80 | x |
| 2019-12-31 | €2.50 | €2.80 | x |
| 2020-12-31 | €2.42 | €2.80 | x |
| 2021-12-31 | €2.45 | €2.80 | x |
| 2022-12-31 | €2.51 | €2.80 | x |
| 2023-12-31 | €2.59 | €2.80 | x |
| 2024-12-31 | €2.67 | €2.80 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Laboratorio Reig Jofre S.A utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 4.85%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 3.06%
- • Asset Turnover: 0.98x
- • Equity Multiplier: 1.61x
- Recent ROE (4.85%) is above the historical average (1.43%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2004 | 8.23% | 13.17% | 0.44x | 1.42x | €-656.99K |
| 2005 | 4.74% | 8.00% | 0.30x | 1.97x | €-4.17 Million |
| 2006 | 3.08% | 5.01% | 0.31x | 1.96x | €-10.22 Million |
| 2007 | 2.73% | 2.51% | 0.48x | 2.25x | €-10.25 Million |
| 2008 | 1.13% | 0.93% | 0.52x | 2.33x | €-11.70 Million |
| 2009 | -47.98% | -33.36% | 0.67x | 2.14x | €-54.27 Million |
| 2010 | -30.83% | -58.23% | 0.21x | 2.50x | €-29.95 Million |
| 2011 | 18.55% | 54.49% | 0.18x | 1.91x | €7.41 Million |
| 2012 | -0.01% | -0.02% | 0.31x | 1.13x | €-8.68 Million |
| 2013 | 1.26% | 3.04% | 0.37x | 1.11x | €-6.61 Million |
| 2014 | 21.24% | 7.80% | 1.39x | 1.96x | €5.02 Million |
| 2014 | 1.95% | 6.94% | 0.18x | 1.53x | €-9.51 Million |
| 2015 | 6.93% | 5.58% | 0.84x | 1.48x | €-3.87 Million |
| 2016 | 5.76% | 4.76% | 0.78x | 1.54x | €-5.65 Million |
| 2017 | 6.23% | 5.26% | 0.83x | 1.44x | €-5.33 Million |
| 2018 | 6.19% | 5.13% | 0.82x | 1.47x | €-5.71 Million |
| 2019 | 2.77% | 2.47% | 0.64x | 1.76x | €-12.88 Million |
| 2020 | 3.07% | 2.47% | 0.73x | 1.72x | €-12.78 Million |
| 2021 | 2.70% | 2.16% | 0.73x | 1.72x | €-13.77 Million |
| 2022 | 4.17% | 2.99% | 0.84x | 1.65x | €-11.36 Million |
| 2023 | 4.60% | 2.98% | 0.96x | 1.62x | €-11.03 Million |
| 2024 | 4.85% | 3.06% | 0.98x | 1.61x | €-11.01 Million |
Industry Comparison
This section compares Laboratorio Reig Jofre S.A's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $595,621,000
- Average return on equity (ROE) among peers: -16.29%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Laboratorio Reig Jofre S.A (RJF) | €216.97 Million | 8.23% | 0.64x | $221.39 Million |
| Almirall S.A. (ALM) | $1.34 Billion | 33.48% | 0.90x | $2.63 Billion |
| Faes Farma SA (FAE) | $747.70 Million | 10.65% | 0.79x | $1.50 Billion |
| Labiana Health S.A. (LAB) | $7.74 Million | -115.49% | 6.85x | $32.50 Million |
| Laboratorios Farmaceuticos ROVI (ROVI) | $287.47 Million | 6.22% | 0.40x | $3.81 Billion |
About Laboratorio Reig Jofre S.A
Laboratorio Reig Jofre, S.A., a pharmaceutical company, engages in the research, development, manufacture, and marketing of pharmaceutical products, raw materials, biotechnological products, nutritional supplements, health products, medical devices, cosmetics, parapharmacy, food, and animal food. Its products also include pharmaceutical technologies products, such as antibiotics, and injectables … Read more